Victor Dzau, MD, is President of the US National Academy of Medicine (NAM), Vice-Chair of the US National Research Council, Chancellor Emeritus of Duke University, and past CEO of Duke Health System. Previously, he was Professor and Chairman of Medicine at Harvard and Stanford. He is recognized globally for a decorated career as a scientist, administrator, and leader. His research laid the foundation for development of ACE inhibitors, lifesaving drugs used globally to treat high blood pressure and congestive heart failure. At NAM, Dzau has launched major initiatives, including the Action Collaborative for Translating Emerging Science, Technology & Innovation; Human Gene Editing Initiative; and Vital Directions for Health & Health Care. He has advanced the concept of academic health science systems and efforts to modernize medical education, research translation, and health infrastructure. In 2024, NAM published The State of the U.S. Biomedical and Health Research Enterprise: Strategies for Achieving a Healthier America. In 2025, NAM co-hosted Sustaining the Biomedical Workforce: Innovative Pathways for Retaining and Supporting Physician-Scientists. Among his many honors are the Gustav Nylin Medal from the Swedish Royal College of Medicine, Research Achievement Award from the American Heart Association, Ellis Island Medal of Honor, Polzer Prize of the European Academy of Sciences and Arts, and Henry Freisen International Prize. He has received 23 honorary doctorates.